Management of inflammatory bowel disease: Past, present and future

Expert Review of Clinical Immunology

Volumn 8, Issue 4, 2012, Pages 303-305

  Keyashian, Kian ^a   Annunziata, Maria Laura ^a   Sakuraba, Atsushi ^a   Hanauer, Stephen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

biologics; Crohns disease; immunomodulator; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CDP 517; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NATALIZUMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VEDOLIZUMAB;

COLONOSCOPY; CROHN DISEASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOSCOPY; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC LINKAGE; HUMAN; IMMUNOGENICITY; INCIDENCE; MAINTENANCE THERAPY; NOTE; RHEUMATOID ARTHRITIS; SACCHAROMYCES CEREVISIAE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 84861397245     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.13     Document Type: Note

References (20)

1. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458-466 (2008).
2. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
3. Farraye FA, Odze RD, Eaden J et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138, 738-745 (2010).
4. Vermeire S, Vermeulen N, Van Assche G et al. (Auto)antibodies in inflammatory bowel diseases. Gastroenterol. Clin. N. Am. 37, 429-438 (2008).
5. Sonu I, Lin MV, Blonski W et al. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol. Clin. N. Am. 39, 559-599 (2010).
6. Vikingsson S, Carlsson B, Almer SH et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther. Drug Monit. 31(3), 345-350 (2009).
7. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330, 1841-1845 (1994).
8. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. 337, 1029-1035 (1997).
9. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
10. Clark M, Colombel JF, Feagan BC et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 133, 312-339 (2007).
11. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am. J. Gastroenterol. 106, 644-659 (2011).
12. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol. Clin. N. Am. 35, 757-773 (2006).
13. Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9(1), 36-41.e1 (2011).
14. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 371, 660-667 (2008).
15. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
16. Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63-70 (2012).
17. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
18. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 60, 780-787 (2011).
19. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. Gastroenterology 132, 1672-1683 (2007).
20. Feagan BG, Greenberg GR, Wild G et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the a4b7 integrin. Clin. Gastroenterol. Hepatol. 6, 1370-1377 (2008).